EXPRESSION OF ROTAVIRUS OUTER CAPSID PROTEIN VP4 BY RECOMBINANT ADENOVIRUS

轮状病毒是婴幼儿严重腹泻的主要原因。 发达国家和发展中国家的儿童。因此，密集的 目前正在努力开发一种有效的疫苗。两个外壳 轮状病毒蛋白，VP7或VP4，每一个都与诱导 在实验动物身上显示的中和抗体是 与抗病有关。血清型特异性一直是 与VP7相关。然而，最近的研究已经开始阐明 基于抗原性的人轮状病毒之间的抗原关系 VP4蛋白的特异性也是如此。人类轮状病毒株 与症状性感染相关，并表现出VP7特异性 血清1、2、3、4或9型各自具有相似的VP4，由 中和试验。 我们选择了猪轮状病毒OSU的外衣壳蛋白VP4作为 模型研究该蛋白在腺病毒载体中的免疫原性。 腺病毒的口服能力使其具有潜在的用途 腺病毒载体用于疫苗生产特别吸引人。在……里面 此外，腺病毒疫苗已经被证明对人类是安全的。 以肠溶胶囊或片剂的形式口服时。

Rotaviruses are the major cause of severe diarrhea in infants and young children in both developed and developing countries. Therefore, intensive efforts are being made to develop an effective vaccine. Two outer capsid rotavirus proteins, VP7 or VP4, are each associated with the induction of neutralizing antibodies that have been shown in experimental animals to be associated with resistance to illness. Serotype specificity has been associated with VP7. However, recent studies have begun to elucidate the antigenic relationships among human rotaviruses based on the antigenic specificity of the VP4 protein as well. Human rotavirus strains that were associated with symptomatic infection and that exhibited VP7 specificity of serotype 1, 2, 3, 4, or 9 each possessed a similar VP4 as determined by neutralization assay. We have chosen the outer capsid protein VP4 of porcine rotavirus OSU as a model to study the immunogenicity of this protein in an adenovirus vector. The ability of adenovirus to be administered orally makes the potential use of adenovirus vectors for vaccine production particularly attractive. In addition, adenovirus vaccines have already been shown to be safe in humans when administered orally as enteric coated capsules or tablets.